Health News Releases

  • Today May 15
April 20, 2021 15:50
PTT Invests in Lotus Pharmaceutical's Strategic Partnership in South East Asia
Lotus Pharmaceutical Co., Ltd. (“Lotus” or “the Company”, Taiwan TWSE ticker: 1795), an Alvogen company, has announced the issuance of new shares through private placement to be acquired by Innobic (A
April 20, 2021 15:20
Humanigen Reports Positive Data With Lenzilumab in the ZUMA-19 CAR-T Phase 1b Study in DLBCL and Plans to Initiate a Potential Registrational Study
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidat
April 19, 2021 09:20
Evobrutinib is the First and Only BTK Inhibitor to Demonstrate Reduction of a Key Biomarker of Neuronal Damage and Inflammation in Patients with MS
Merck, a leading science and technology company, will present data from a Phase II placebo-controlled randomized trial at the 2021 American Academy of Neurology (AAN) Annual Meeting showing that the i
April 16, 2021 14:00
ROSALIND, HELiXrUS and Geninus Partner to Bring Powerful New Single Cell Analysis Services to Cancer Researchers
ROSALIND®, a software leader in extracting meaningful insights from diverse pools of life science data, today announced that it has partnered with two Seoul-based technology providers to enable a powe
April 15, 2021 11:51
Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer
Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced the extension and expansion of their joint Virtual Research and Development Center (VRDC) to explore new mole
April 14, 2021 17:40
RubrYc Therapeutics Announces a Research Collaboration and License Option Agreement With Zai Labs
RubrYc Therapeutics, Inc., a pre-clinical biotherapeutics company developing epitope selective therapies, today announced that it has entered into a research collaboration and license option agreement
April 14, 2021 15:50
Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity
Boehringer Ingelheim and Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) announced the initiation of two Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults who are overweight or obes
April 14, 2021 15:30
LintonPharm Announces Authorization from China Health Authority (NMPA) to Proceed with a Phase 1/2 Trial Evaluating Catumaxomab for the treatment of Non-Muscle Invasive Bladder Cancer
LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell engaging bispecific antibodies for cancer immunotherapy, today announced that China’s
April 14, 2021 11:34
Illumina Named One of Singapore’s Best Employers
Illumina, Inc., today announced, for the second consecutive year, Illumina is honored as one of Singapore’s Best Employers in a survey sponsored by The Straits Times and the marketing firm Statista. I
April 13, 2021 16:10
Merck Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer With New Published Data and Initiation of Phase II Trial With Registrational Intent
Merck, a leading science and technology company, today announced key clinical advancements for berzosertib (M6620), an investigational, potent and selective ataxia telangiectasia and Rad3-related (ATR
April 13, 2021 14:40
Diaceutics Appoints Yvanka Gilliam as Vice President of Operations, Asia Pacific
Diaceutics PLC, (AIM: DXRX), today announces the appointment of Yvanka Gilliam as Vice President of Operations, Asia Pacific (APAC). In her new role, Yvanka will be responsible for managing busines
April 13, 2021 10:00
Deargen Announces New Model of Optimizing Drug Candidate Molecules With Enhanced Performance by Nearly Double Compared to Existing Models
Deargen, an artificial intelligence (AI)-based drug discovery and development biotech company, announced on April 9 that it presented study results on controlled molecule generator (CMG) technology at
April 12, 2021 10:30
Humanigen Announces Positive Results From Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme
Humanigen, Inc. (Nasdaq:HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™,
April 08, 2021 18:36
Galderma Announces Publication of Phase 2b Trial Results Demonstrating the Rapid and Long-lasting Benefits of Nemolizumab in Clinical Trial Subjects With Uncontrolled Atopic Dermatitis
Galderma today announced that the Journal of the European Academy of Dermatology and Venereology (JEADV) has published full results from a post-hoc analysis of the phase 2b study of its investigationa
April 08, 2021 14:40
Milestone Study Shows Natural Molecule, Urolithin A, Can Improve Muscle Function and Life Expectancy in Mice With Muscle Dystrophy
Progression of Duchenne Muscle Dystrophy (DMD) can be delayed in mice by supplementing their diets with Urolithin A, according to new results reported today. The findings, published in Science Transla
April 07, 2021 16:20
Humanigen Announces Closing of Public Offering of Common Stock
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm” with its lead drug candidat
April 07, 2021 15:00
Erbe Elektromedizin to acquire Maxer Endoscopy
An investment to strengthen our operating room presence “This acquisition reflects our determination to become a solution provider for surgeries and procedures where visualization is critical. We w
April 07, 2021 11:30
Study Investigates the Effects of Ventilatory Rescue Therapies on the Cerebral Oxygenation of COVID-19 Patients Using Masimo O3®
Masimo (NASDAQ: MASI) today announced the results of a prospective, observational study published in Critical Care in which researchers in Genoa, Italy, evaluated the impact of a variety of rescue the
April 05, 2021 10:30
Nanox Announces FDA Clearance of 510(k) for Single Source Nanox.ARC Digital X-Ray
NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, announced today that its single-source Nanox.ARC digital x-ray technology has received 5
April 05, 2021 10:10
CoVIg-19 Plasma Alliance Announces Topline Results from NIH-Sponsored Clinical Trial of Investigational COVID-19 Hyperimmune Globulin Medicine
The CoVIg-19 Plasma Alliance today announced that the Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial sponsored and funded by the National Institute of Allergy a
April 02, 2021 15:10
City of Hope and Hospital Israelita Albert Einstein Sign Agreement to Advance Cancer Care in Latin America
City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, today announced that it will extend its leading-edge cancer expertise to South America via an educatio
April 01, 2021 23:15
Takeda Hosts Wave 1 Pipeline Market Call
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will host a conference call on April 6, 2021 to provide updates on select New Molecular Entities (NMEs) in
April 01, 2021 15:40
Takeda Completes Sale of Select OTC and Non-Core Assets to Orifarm
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to Orifarm Group (“Orifarm”) for
April 01, 2021 14:45
Patient Safety Movement Foundation Announces Winners of Lewis Blackman Leadership Award
The Patient Safety Movement Foundation (PSMF), a global non-profit committed to achieving zero preventable patient harm and death across the globe by 2030, honored Oscar San Roman Orozco and Nicholas
April 01, 2021 13:40
Xlife Sciences AG (XLS): 2020 Financial Results
In 2020, Xlife Sciences AG (XLS) significantly increased its profit to 21.2 million Swiss francs compared to the previous year (1.03 million). The increase is based on the transaction and the capital
25 per page50 per page75 per page100 per page